SUSAN CAIN: Open Payments
NPI 1033227863 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,236 in 101 payments from 13 companies in 2025. Trend: 2023 $1,116 · 2024 $2,092 · 2025 $3,236
Food & beverage: $2,888Education: $348
| Company | Payments | Amount |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 25 | $1,274 |
| Janssen Biotech, Inc. | 32 | $863 |
| Astellas Pharma US Inc | 7 | $313 |
| Ferring Pharmaceuticals Inc. | 6 | $219 |
| Sumitomo Pharma America, Inc. | 13 | $217 |
| ABBVIE INC. | 9 | $179 |
| PFIZER INC. | 3 | $51 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $26 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 1 | $21 |
| Telix Pharmaceuticals | 1 | $20 |
Products named: PROVENGE, ERLEADA, ADSTILADRIN, BOTOX, RYBREVANT, GEMTESA, XTANDI, ORGOVYX.
Industry payments across WA — which companies pay providers there.
